Merck in $3.85bn Idenix buy to bolster hep C outlook
This article was originally published in Scrip
Merck & Co is hoping Idenix Pharmaceuticals will help it remain a significant player in the hepatitis C space as it watches Gilead's Sovaldi (sofosbuvir) smash pharmaceutical sales records (scripintelligence.com, 23 April 2014).
You may also be interested in...
Private Company Edition: Atea and Phlow receive big money for big COVID-19 problems – treatments and manufacturing capacity. Also, Cowen raises a $493m fund and antifungal developer Amplyx increases series C round to $90m, among other recent VC deals.
Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.
Pharma ends HCV development, pulling plug on next-generation two-drug and three-drug combos for hepatitis C and rendering the $3.9bn buyout of Idenix in 2014 a failed gambit.